TSC2 and non-small cell lung carcinoma: We further reanalyzed the data of 75 patients with NSCLC from Hellmann’s dataset (11) and found an increase in both nonsynonymous mutation burden and predicted neoantigens in TSC1/TSC2-mutant tumors (both P < 0.01, FDR = 0.016; Fig. 4K).